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Proteinuria is a major health-care problem that affects several
hundred million people worldwide. Proteinuria is a cardinal
sign and a prognostic marker of kidney disease, and also an
independent risk factor for cardiovascular morbidity and
mortality. Microalbuminuria is the earliest cue of renal
complications of diabetes, obesity, and the metabolic
syndrome. It can often progress to overt proteinuria that in
10–50% of patients is associated with the development of
chronic kidney disease, ultimately requiring dialysis or
transplantation. Therefore, reduction or prevention of
proteinuria is highly desirable. Here we review recent novel
insights into the pathogenesis and treatment of proteinuria,
with a special emphasis on the emerging concept that
proteinuria can result from enzymatic cleavage of essential
regulators of podocyte actin dynamics by cytosolic cathepsin
L (CatL), resulting in a motile podocyte phenotype. Finally,
we describe signaling pathways controlling the podocyte
actin cytoskeleton and motility and how these pathways
can be manipulated for therapeutic benefit.
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TYPES OF PROTEINURIA
In a healthy person, urinary protein excretion is less than
150mg/day and consists mainly of filtered plasma proteins
(60%) and tubular Tamm-Horsfall proteins (40%). The main
plasma protein in the urine is albumin, constituting about
20% of daily protein excretion. In healthy subjects, the
daily amount of urinary albumin is less than 20mg
(13.8mg/min).1 Proteinuria usually reflects an increase in
glomerular permeability for albumin and other plasma
macromolecules.1 A 24-h urine collection containing more
than 150mg of protein is considered pathological. There are
several basic types of proteinuria; for example, glomerular,
tubular, overflow, and exercise-induced (Table 1). Glome-
rular proteinuria is the most common form (around 90%).
Low molecular weight molecules, such as b2-microglobulin,
amino acids, and immunoglobulin light chains, have a
molecular weight of about 25 kDa (albumin is 69 kDa). These
smaller proteins are readily filtered across the glomerular
filtration barrier and then fully reabsorbed by the proximal
tubule. A variety of diseases that affect tubular and interstitial
cell integrity impair the tubular reabsorption of these
molecules.2 Some forms of glomerular diseases are also
accompanied by tubular injury and tubular proteinuria.3
Pathological processes, such as multiple myeloma with a
production of paraproteins, can result in increased excretion
of low molecular weight proteins into the urine, a process
termed overflow proteinuria. In this scenario, proteinuria
results from the amount of filtered proteins exceeding the
reabsorptive capacity of the proximal tubule.4 Dynamic
exercise can also result in increased urinary excretion of
proteins, predominantly of plasma origin, during and
following physical exercise. A number of terms have been
used to describe this phenomenon—post-exercise protein-
uria, athletic pseudonephritis, exercise proteinuria, or
exercise-induced proteinuria.5 Maximal rates of proteinuria
occur approximately 30min after exercise, with a resolution
toward resting levels within 24–48 h. The magnitude of
proteinuria varies from near normal to heavy (47 g/day),
with the greatest levels up to 100 times that of rest observed
after high-intensity exercise, such as a marathon. It is note-
worthy that post-exercise proteinuria is transient in nature
and not associated with any particular renal disease, raising
the intriguing possibility that at least some forms of protein-
uria (e.g., post-exercise, post-prandial, infection-associated)
may reflect a normal, physiological response of the human
body (Table 1). In this review, we focus on the emerging
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concept that proteinuria can result from enzymatic cleavage of
essential regulators of podocyte actin dynamics by cyto-
solic cathepsin L (CatL). Because of space limitations, genetic6
and other causes of proteinuria7 will not be discussed in detail.
CONSTITUENTS OF THE KIDNEY FILTRATION BARRIER
The kidney glomerulus (Figure 1a) is a highly specialized
vascular bed that ensures the selective ultrafiltration of
plasma so that the essential proteins are retained in the
blood.8–10 The glomerular basement membrane (GBM)
provides the primary structural support for the glomerular
tuft. The basic unit of the glomerular tuft is a single capillary.
The fenestrated glomerular endothelial cells and mesangial
cells are located inside the GBM, whereas podocytes are
attached to the outer aspect of the GBM (Figure 1a). The
glomerular capillaries function as the filtration barrier.9,11
The filtration barrier is characterized by distinct charge and
size selectivity, thereby ensuring that albumin and other
plasma proteins are retained in the circulation.9,11 Protein-
uria occurs when the permeability of the glomerular barrier is
increased.11 Direct proof for this concept came from human
monogenetic studies showing that mutations affecting podo-
cyte proteins, including a-actinin-4,12 CD2AP,13 nephrin,14
PLCE1,15 podocin,16 and TRPC6,17,18 lead to renal disease
owing to disruption of the filtration barrier and rearrange-
ment of the podocyte actin cytoskeleton.6,7 Additional
proteins regulating the podocyte actin cytoskeleton, such
as Rho GDIa,19,20 podocalyxin,21 FAT1,22 Nck1/223,24 and
synaptopodin,25,26 are also of critical importance for
sustained function of the glomerular filtration barrier.7 Some
years ago, using two-photon microscopy, Russo et al.27
claimed that the normal kidney filters nephrotic levels of
albumin retrieved by proximal tubule cells. However, several
recent studies convincingly refuted this alternative concept of
a ‘leaky’ glomerular barrier.28–30 Using two-photon micro-
scopy as well, Tanner28 and Peti-Peterdi30 independently and
directly confirmed the classical view that the glomerular filter
is the primary barrier for albumin and that the glomerular
sieving coefficient for albumin is extremely low.28–30 The
values determined by Tanner28 and Peti-Peterdi30 are somewhat
higher than most values determined by kidney micropuncture,
but they are still an order of magnitude less than the values
reported by Russo et al.27 Tanner28 and Peti-Peterdi30 also
demonstrated how the abnormally high glomerular sieving
coefficient postulated by Russo et al. most likely resulted from
technical limitations of the experimental approach.28,30 In
conclusion, the classic view of a highly size- and charge-
selective glomerular barrier still holds.28,31–33
PODOCYTES ARE PERICYTE-LIKE CELLS WITH AN
ACTIN-BASED CONTRACTILE APPARATUS
Differentiated podocytes are mesenchymal-like cells that arise
from epithelial precursors during renal development.34
Similar to pericytes, podocytes never embrace a capillary in
total.10 Podocytes consist of three morphologically and
functionally different segments: a cell body, major processes,
and foot processes (FPs).10 From the cell body, major
processes arise that split into FP (Figure 1a). FPs contain
an actin-based cytoskeleton that is linked to the GBM.7
Podocyte FPs form a highly branched interdigitating network
with FPs of neighboring podocytes connected by the slit
diaphragm (SD) (Figure 1a). The SD is a modified adherens
junction35 that covers the 30–50 nm wide filtration slits
(Figure 1a), thereby establishing the final barrier to urinary
protein loss.8 The extracellular portion of the SD is made up
of rod-like units that are connected in the center to a linear
bar, forming a zipper-like pattern, with pores about the same
size as or smaller than albumin.10 The function of podocytes
is largely based on their complex cell architecture, in parti-
cular on the maintenance of the normal FP structure with
their highly ordered parallel contractile actin filament
bundles7,36 (Figure 1a). FPs are functionally defined by
three membrane domains: the apical membrane domain, the
SD, and the basal membrane domain or sole plate that is
associated with the GBM.7,37 All three domains are physically
and functionally linked to the FP actin cytoskeleton. Proteins
regulating the plasticity of the podocyte actin cytoskeleton
are therefore of critical importance for sustained function of
the glomerular filter.7
SIGNAL TRANSDUCTION AT THE SD REGULATES PODOCYTE
ACTIN DYNAMICS
At the SD, multiple membrane proteins are present that are
connected to the actin cytoskeleton through a variety of
adaptor and effector proteins that may function as a key
sensor and regulator of the permanent changes in FP shape
and length.7 Changes in podocyte FP dynamics need to be
precisely coordinated with FPs of neighboring podocytes,
thereby preserving the integrity of the filtration barrier
during FP movements, with functional coupling of opposing
FPs and signaling cascades on both sides of the SD.7
Mutations in the NPHS1 gene encoding for the SD protein
nephrin have been identified as the cause of congenital
nephrotic syndrome of the Finnish type.14 It is noteworthy
that nephrin is connected to the actin cytoskeleton through
several adapter proteins and has a pivotal part in the
Table 1 | Types of proteinuria
Types Characteristics
Glomerular Most common form, up to 90%
Feature of chronic kidney disease
Loss of albumin and higher molecular weight proteins
Tubular Low molecular weight proteins, such as
b2-microglobulin
Overflow Increased production, that is, light chains in multiple
myeloma
Post-exercise Transient benign
Can be up to 10 g/day
Post-prandial Transient physiological proteinuria
Possibly through insulin action in podocytes
Infection- Physiological response
associated Mediated by toll-receptors
Possibly involved in clearing pathogens from the
circulation
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regulation of podocyte actin dynamics.7,38 Among others
(reviewed in detail by Faul et al.7), a recently discovered
signaling pathway couples nephrin to the actin cytoskeleton
through the adaptor protein Nck.23,24 After nephrin phosphor-
ylation by Fyn,39 Nck binds to phospho-nephrin and Nck binds
to N-WASP.23,24 This in turn leads to the activation of the
Arp2/3 complex, a major regulator of actin dynamics.7,23,24,38
PODOCYTE DYSFUNCTION IS THE COMMON THREAD IN
PROTEINURIC DISEASES
Podocytes can be injured in many forms of human and
experimental glomerular disease, including minimal change
disease (MCD), focal segmental glomerulosclerosis (FSGS),
membranous glomerulopathy, diabetic nephropathy, and
lupus nephritis.8,37 Characteristic changes are actin cyto-
skeleton reorganization of the involved FP, which typically
leads to FP effacement and SD disruption12,40 (Figure 1b).
Interference with any of the three FP domains changes the
actin cytoskeleton from parallel contractile bundles36 into a
dense network with FP effacement (reflected by the
simplification of the FP structure and loss of the normal
interdigitating pattern) (Figure 1b) and proteinuria.37 Causes
of FP effacement and proteinuria include the following:
(i) changes in SD structure or function,39,41,42 (ii) inter-
ference with the GBM or the podocyte–GBM interaction,43–49
(iii) dysfunction of the podocyte actin cytoskeleton,12,20,24,38,50–52
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Figure 1 |Podocyte structure in health and disease. (a) Left: the glomerulus contains a capillary tuft that receives primary structural support
from the glomerular basement membrane (GBM). Glomerular endothelial cells (E) embracing the capillary lumen (CL), and mesangial cells (M) are
located on the blood side of the GBM, whereas podocyte foot processes (FP) cover the outer aspect of the GBM. Podocyte cell bodies (CB) and
major processes (MT) are floating in primary urine in Bowman’s space (BS). Along its route from the blood space to the urine space (red arrow),
the plasma ultrafiltrate passes sequentially through the fenestrated glomerular capillary endothelium, the GBM, and the filtration slits between
neighboring podocyte foot processes with the interposed slit diaphragms. AA, afferent arteriole; DT, distal tubule; EE, efferent arteriole;
PT, proximal tubule. Middle: scanning electron microscopy (SEM) illustrates the complexity of podocyte morphology. Looking from Bowman’s
space, a cell body (CB) is seen that is linked to the capillaries by major processes (MP). Podocyte foot processes (FP) arise from MP and form
the signature interdigitating pattern with FPs of neighboring podocytes, leaving in between the filtration slits. Only FPs are in direct contact with
the GBM. Right: transmission electron microscopy (TEM) view (top) of the glomerular filtration barrier consisting of fenestrated endothelium (E),
GBM, and podocyte FP with the interposed slit diaphragm (SD) covering the filtration slits. Top view (bottom) of normal FPs. In healthy podocytes,
FPs regularly interdigitate. The highly organized parallel contractile actin bundles of interdigitating FPs from two adjacent podocytes are
shown in red and yellow. Microtubules of MPs are shown in blue. (b) Left: in nephrotic syndrome with proteinuria, FPs lose their normal
interdigitating pattern and show effacement instead. Middle: the loss of the normal cytoarchitecture and the development of meandering cell
borders can be best viewed by SEM. Right: effaced FPs develop a continuous band of cytoplasm containing a dense band of short branched actin
filaments (*). Top view (bottom) of effaced podocyte FPs showing the loss of the replacement of the regular interdigitating pattern by a simplified
meandering cell border between effaced FPs. A continuous sheet of cytoplasm develops that is filled with reorganized, short, branched actin
filaments (green).
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(iv) modulation of the negative surface charge of podocytes,53–55
and (v) activation of CatL-mediated proteolysis56–60 (see below).
In addition, disturbances in the transcriptional regulation of
podocyte function,61 modulation of vascular endothelial growth
factor,62,63 transforming growth factor-b,64 adiponectin,65
notch,66,67 or aPKClamda68,69 signaling can also contribute
to the pathogenesis of FP effacement and proteinuria. The early
structural changes in podocyte morphology, such as FP
effacement and SD disruption, are fully reversible (Figure 2).
From a clinical point of view it is important to recognize
that persistent podocyte injury harbors great risk to severe
and progressive glomerular damage70,71 (Figure 2). The
persistence of podocyte injury can cause podocyte cell death
(through apoptosis or necrosis) or podocyte detachment
from the GBM.72 Through a series of ensuing changes that
have been reviewed in detail elsewhere,73 the loss of podocyte
ultimately leads to glomerulosclerosis and end-stage renal
failure.73 The contribution of proteinuria itself to the
progression of end-stage renal failure is a matter of debate.74
Some studies have suggested that proteinuria causes podo-
cyte75 or tubulointerstitial inflammation and progressive
injury.76 On the other hand, severe experimental protein
loss across the glomerular filter caused by repeated injection
to rats with anti-nephrin antibody 5-1-6 did not lead to
progressive renal failure.77 More importantly, patients with
MCD or membranous glomerulopathy can present over
years with nephrotic-range proteinuria without progressing
to end-stage renal failure (Figure 2). Thus, the role of
proteinuria in the progression of kidney failure probably
depends on the type and the route of protein loss; that is,
protein loss across the filtration barrier versus misdirected
filtration into the periglomerular interstitium.73,78
INCREASED FP MOTILITY AND THE ONSET OF PROTEINURIA
It has long been know that the podocyte FP actin
cytoskeleton is highly dynamic, although the underlying
mechanisms remained ill defined. Testaments to a dynamic
FP regulation are experiments that used perfusion of rat
kidneys with the polycation protamine sulfate (PS). This
treatment causes FP effacement and SD disruption within
15min79 and tyrosine phosphorylation of nephrin.24 The
reperfusion with heparin for another 15min can reverse
PS-induced FP effacement80 and nephrin phosphorylation.24
PS-induced FP effacement involves the active reorganization of
actin filaments,21,54 and disruption of the actin cytoskeleton by
cytochalasin can prevent PS-induced FP effacement.81
THE ROLE OF CYTOSOLIC CatL AND B7-1 IN THE
PATHOGENESIS OF PROTEINURIA
CatL is a member of the cathepsin family of cysteine
proteases, which are involved primarily in protein breakdown
in the lysosome.82 Two recent studies described a function for
extralysosomal CatL in the nucleus.83,84 Regarding the role of
CatL in kidney filter function, previous studies showed that a
CatL inhibitor can reduce experimental proteinuria,85 but the
underlying molecular mechanism remained unclear. In 2004,
we reported that the onset of experimental proteinuria is
associated with the induction of CatL expression and activity
in podocytes.58 This study introduced the concept that the
onset of proteinuria represents a migratory event in podocyte
FP that is caused by the activation of CatL58 (Figure 3).
Subsequently, we found that a cytoplasmic variant of CatL in
podocytes is required for the development of proteinuria in
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Figure 2 |Consequences of podocyte injury. Podocytes can be
injured in many human and experimental glomerular diseases,
leading to structural changes, such as foot processes (FP)
effacement and slit diaphragm (SD) disruption that are
reversible.124 Persistence of podocyte injury can cause cell death
or detachment of podocytes from the glomerular basement
membrane (GBM).72 The resulting loss of podocyte will ultimately
lead to irreversible glomerulosclerosis and end-stage renal failure
(ESRD).73 The role of proteinuria in the progression of ESRD is a
matter of debate. In some patients, nephrotic-range proteinuria
can persist over years without progression to ESRD.
Normal glomerular filtration barrier
Stationary podocyte
Podocyte insult
Induction of cytoplasmic cathepsin L
Motile podocyte
Proteinuria
Figure 3 | Induction of cathepsin L in podocytes precedes
FP effacement and proteinuria. Upon an insult, stationary
podocytes upregulate cytoplasm cytosolic cathepsin L expression
and activity and develop motile podocyte foot processes (FPs).
This migratory response leads to FP effacement, slit diaphragm
remodeling, and proteinuria.58
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mice through a mechanism that involves the cleavage of the
large GTPase dynamin60 and synaptopodin57 (Figure 4). The
clinical relevance of these findings was underscored by the
observation that increased podocyte CatL expression was
found in a variety of human proteinuric kidney diseases,
including MCD, membranous glomerulopathy, FSGS, and
diabetic nephropathy.60 Together these results support the
notion that CatL-mediated proteolysis may have a key
function in the development of many forms of proteinuria.60
The lipopolysaccharide (LPS) model of proteinuria also
helped identifying an unanticipated role for costimulatory
molecule B7-1 in podocytes as an inducible modifier of
glomerular permselectivity86 (Figure 4). It is noteworthy that
the expression of B7-1 in podocytes is correlated with the
severity of human lupus nephritis, and mice lacking B7-1 are
protected from LPS-induced proteinuria, suggesting a
functional link between podocyte B7-1 expression and
proteinuria.86 Functionally, LPS signaling through Toll-like
receptor-4 reorganized the actin cytoskeleton of cultured
podocytes.86 These findings also suggest a function for B7-1
in danger signaling by podocytes.86,87 LPS causes proteinuria
by selectively targeting podocytes because podocyte-specific
overexpression of CatL-resistant dynamin60 or synapto-
podin57 (see below) is sufficient to safeguard against protein-
uria. Key effectors of the LPS-induced proteinuria have been
detected in podocytes in vivo in animals and in biopsies from
patients with proteinuric kidneys diseases, including B7-1,86
CatL,60 and urokinase plasminogen activator receptor
(uPAR).42 Although there is no report about cytosolic variant
of cathepsin L in the proximal tubule, CatL is highly
expressed in the tubular lysosomes. On the basis of published
data, we do not think that there is experimental evidence or
need for a role of tubular CatL in the pathogenesis of
albuminuria, because the podocyte-specific interference with
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Figure 4 | Integrative model for the regulation of podocyte actin dynamics in health and disease. Induction of cytoplasmic cytosolic
cathepsin L (CatL) enzyme is a common downstream effector in many glomerular diseases. Lipopolysaccharide (LPS) or various other
proximal signals induce the expression of B7-186 and CatL58,60 in podocytes, which cause proteinuria through the increased degradation of
synaptopodin57 and dynamin.60 Phosphorylation of synaptopodin by PKA or CaMKII promotes 14-3-3 binding, which protects synaptopodin
against CatL-mediated cleavage, thereby stabilizing synaptopodin steady-state levels.57 Synaptopodin suppresses IRSp53–Mena-mediated
filopodia by blocking the binding of Cdc42 and Mena to IRSp5396 and induces stress fibers by competitive blocking the Smurf-1-mediated
ubiquitination of RhoA.26 Synaptopodin also prevents the CatL-mediated degradation of dynamin.57 Dephosphorylation of synaptopodin
by calcineurin abrogates the interaction with 14-3-3. This renders the CatL cleavage sites of synaptopodin accessible and promotes the
degradation of synaptopodin.57 LPS or other proximal signals can also activate Cdc42 and Rac1 through uPAR–b3-integrin signaling,42
through the loss of synaptopodin-mediated inhibition of Cdc42 signaling,96 or through Nef–Src-mediated activation of Rac1.52 As a
consequence, the podocyte actin cytoskeleton shifts from a stationary to a motile phenotype, thereby causing foot process effacement and
proteinuria. CsA and the CatL inhibitor E64 safeguard against proteinuria by stabilizing synaptopodin and dynamin steady-state protein
levels in podocytes, FP(4)-Mito by blocking Cdcd42–IRSp53–Mena signaling,96 cycloRGDfV by blocking uPAR–b3-intergrin signaling,42
NSC23766 by blocking Rac1, and epleronone by blocking aldosterone signaling.20
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calcineurin–CatL signaling is sufficient to cause induction of
albuminuria, or protection thereof, respectively.42,57,58,60
ACTIVATION OF PROMIGRATORY Cdc42 AND Rac1 IN
PODOCYTES CAUSES FP EFFACEMENT AND PROTEINURIA
The Rho family of small GTPases (RhoA, Rac1, and Cdc42)
controls signal-transduction pathways that influence many
aspects of cell behavior, including actin dynamics.88–90 At the
leading edge, Rac1 and Cdc42 promote cell motility through
the formation of lamellipodia and filopodia, respectively. On
the contrary, RhoA promotes the formation of contractile
actin–myosin containing stress fibers in the cell body and
at the rear.88,89,91 We will now discuss how the onset of
proteinuria can be caused by the activation of Cdc42 and
Rac1 signaling and concomitant decrease of RhoA signaling
in podocytes.7 uPAR is a glycosylphosphatidylinositol-
anchored protein that has been shown to be a proteinase
receptor for urokinase, but has also been involved in non-
proteolytic pathways, mainly through its ability to form
signaling complexes with other transmembrane proteins, such
as integrins, caveolin, and G-protein-coupled receptors.92
uPAR is induced and activated in podocytes in response
to proteinuric stimuli, such as LPS or PAN (Figure 4), leading
to increased podocyte motility in vitro and FP effacement
and proteinuria in vivo.42 Lipid raft-associated uPAR forms
a complex with b3-integrin, thereby causing the activation
of b3-integrin. This in turn promotes Cdc42 and Rac1
signaling, thereby causing podocyte FP effacement and
proteinuria.42 Proteinuria caused by uPAR–b3-integrin signal-
ing can be prevented and reduced by cycloRGDfV,42 a selective
inhibitor of avb3-integrin.
93 The activation of Rac1 signaling
in podocytes also contributes to proteinuria in human
immunodeficiency virus-associated nephropathy52 and
RhoGDIalpha knockout mice.20 Rac1-induced proteinuria
can be blocked by the inhibition of Rac1 or blocking its
downstream target aldosterone20 (Figure 4). Thus, the activa-
tion of promigratory Cdc42 and Rac1 signaling in podocytes
is a widespread cause of FP effacement and proteinuria.
SYNAPTOPODIN IS A KEY STABILIZER OF THE PODOCYTE
ACTIN CYTOSKELETON
The actin-binding protein, synaptopodin, which is highly
expressed in podocytes,94 exists in three isoforms: neuronal
Synpo-short, renal Synpo-long, and Synpo-T.25 Synapto-
podin mutant mice lacking Synpo-short and Synpo-long
upregulate Synpo-T protein expression in podocytes, thereby
rescuing kidney filter function during development.25 They
do, however, display impaired recovery from PS-induced FP
effacement and LPS-induced proteinuria.25 Bigenic hetero-
zygosity for synaptopodin and CD2AP results in proteinuria
and FSGS-like glomerular damage,95 thereby underscoring
the importance of synaptopodin and CD2AP for sustained
kidney filter function. Mechanistically, synaptopodin induces
stress fibers by stabilizing RhoA26 and suppresses filopodia by
disrupting Cdc42–IRSp53–Mena signaling complexes96 (Fig-
ure 4). The Mena inhibitor, FP(4)-Mito, suppresses aberrant
filopodia formation in synaptopodin knockdown podocytes
in vitro, and when delivered into mice protects against LPS-
induced proteinuria.96 Thus, synaptopodin is an antagonistic
regulator of RhoA and Cdc42 signaling that stabilizes the
kidney filter by blocking the reorganization of the podocyte
actin cytoskeleton into a migratory phenotype (Figure 4).
CURRENT CLINICAL THERAPIES TARGETING PROTEINURIA
When considering antiproteinuric therapy, one has to
distinguish between acute new-onset proteinuria and protei-
nuria in the setting of chronic kidney disease. It is widely
accepted that proteinuria reduction is an imperative
therapeutic goal in chronic proteinuric kidney disease.97 On
the basis of large randomized clinical trials, angiotensin-
converting enzyme inhibitor (ACEI) and angiotensin II (Ang
II) type 1-receptor blockers (ARB) therapy have developed
into the most important antiproteinuric and renoprotective
interventions.97 Many of the beneficial effects of these types
of agents toward proteinuria can be explained by the blood
pressure-lowering effect that leads also to a lowered
glomerular filtration pressure. However, there are also
numerous non-blood pressure-related effects of ACEI and
ARB that can act directly on podocyte through targeting a
local renin–angiotensin system.97,98 The inhibition of the
renin–angiotensin system is also associated with restoration
of nephrin expression in both experimental and human
diabetic nephropathy.99 The expression of nephrin was
retained at the SD when rats with experimental membranous
nephropathy were treated with an ACE inhibitor or with an
Ang II receptor antagonist. The resulting well-known effect of
these drugs—limiting proteinuria in animal models of
progressive nephropathy—therefore may depend on the
capacity of Ang II blockers to preserve podocyte function.100
In a rat model of spontaneous proteinuria, the development
of proteinuria is associated with the relocation of zonula
occludens-1 from the SD to the podocyte cell body.101 The
ACE inhibitor, lisinopril, not only prevented proteinuria but
also redistributed zonula occludens-1 to the SD.101 Most
direct support for a role of Ang signaling in podocytes as a
cause of proteinuria and FSGS comes from a study with
transgenic rats overexpressing an AT1 receptor selectively in
podocytes.102 Hence, the renoprotective effects of ACEI and
ARBs are associated with the preservation of podocyte
function. Other examples where ACEI and ARB act benefitial
on the glomerular filtration barrier are the modulation of
podocyte function through modification of extracellular
matrix, proinflammatory cytokine production, and blockade
of the deleterious actions of radical oxygen species.97 There
are numerous other interventions (Table 2) that have been
shown to be antiproteinuric and renoprotective.76 Unfortu-
nately, testing each of these antiproteinuric therapies in
randomized clinical trials is presently not feasible. Interest-
ingly, the inhibition of aldosterone by specific inhibitors can
reduce proteinuria and Rac1 signaling independent of blood
pressure, as shown in normotensive RhoGDIa knockout
mice20 (Figure 4).
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In contrast to chronic forms of proteinuria, treatment of
new-onset proteinuria often includes immunomodulatory
drugs, such as glucocorticoids, cyclosporine A (CsA), FK506,
mycophenolate mofetil, and Rituximab.103 What is the
rationale for using immune-suppressing agents in treating
acute proteinuria? Historically, some rationale derived
from the ‘soluble mediator hypothesis’ that MCD is
a disorder of the immune system in which release of
T-cell-derived circulating factor(s) causes proteinuria.104
Despite the lack of convincing experimental support, this
hypothesis has remained the dominant paradigm for the
treatment of nephrotic syndrome, and the antiproteinuric
effect of glucocorticoid therapy was attributed to its T-cell-
repressing action.103 However, recent studies have shown that
glucocorticoid receptors are present on podocytes and
translocate to the podocyte nucleus upon dexamethasone
treatment.105 Glucocorticoids can also increase the stability
of actin filaments, increase actin polymerization, and
activate cytoskeleton-associated kinases in podocytes.105
These findings suggest that the antiproteinuric effect of
glucocorticoids is, at least in part, mediated by a direct
effect on the podocyte actin cytoskeleton independent of
immunosuppression.
THE ANTIPROTEINURIC EFFECT OF CsA RESULT FROM THE
STABILIZATION OF SYNAPTOPODIN IN PODOCYTES
Calcineurin is a ubiquitously expressed serine/threonine
phosphatase.106 The best-characterized function of calcine-
urin is the regulation of nuclear factor of activated T cells
(NFAT) signaling. The immunosuppressive action of the
calcineurin inhibitor, CsA, stems from the inhibition of
NFAT signaling in T cells.107 CsA can also induce a remission
of proteinuria caused by diseases, including MCD and
FSGS.103 T-cell dysfunction is associated with some forms
of proteinuria, including a subset of MCD in children.
Therefore, it is has been assumed that the antiproteinuric
effect of CsA results from the inhibition of NFAT signaling in
T cells.103 CsA can also reduce proteinuria in human108 and
experimental109 Alport’s syndrome, a non-immunological
disease, raising doubts about the above hypothesis. Moreover,
LPS-induced proteinuria can develop independent of
T cells,86 and mice lacking synaptopodin display impaired
Table 2 | Antiproteinuric strategies (modified from Wilmer et al.76)
Intervention Goal/comment
Level 1
Control blood pressure (BP) The greater the proteinuria, the greater the benefit of lowering BP
Angiotensin-converting enzyme inhibitor (ACEI)
therapy
Use ACEI even if normotensive
Angiotensin II type 1-receptor blocker (ARB)
therapy
Proven antiproteinuric and renoprotective therapy
Combination ACEI and ARB therapies Adding ARB to maximum ACEI appears to reduce proteinuria further
Avoid dihydropyridine calcium-channel blockers
(DHCCBs) unless needed for BP control
DHCCBs are excellent antihypertensive agents, but they are not antiproteinuric and may
promote kidney disease progression; ARB therapy may mitigate these effects
b-Blocker therapy b-Blocker therapy is antiproteinuric compared with DHCCB therapy
Control protein intake Goal is 0.7–0.8 g/kg/day. Effect on proteinuria is nearly the same as that of the low BP goal
Level 2
Restrict NaCl intake Goal is 80–120mmol/day (E2.0 to 3.0 g Na).
Control fluid intake Goal is urine volume o2.0 l/day unless higher fluid intake is needed for specific reasons
Nondihydropyridine calcium-channel blocker
therapy
This CCB class is considered antiproteinuric
Control blood lipids Statins are considered antiproteinuric and renoprotective
Aldosterone antagonist therapy Spironolactone is antiproteinuric in humans and in animal models independent of BP control
Smoking cessation Cigarette smoking in humans increases proteinuria/albuminuria and is associated with faster
kidney disease progression
Avoid estrogen/progestin replacement therapy
in postmenopausal women with kidney disease
Estrogens may have renoprotective effects that explain slower progression of kidney disease
in premenopausal women compared with men of the same age but may have adverse effects
in postmenopausal women
Supine/recumbent posture when feasible.
Avoid severe exertion
Nephrotic-range proteinuria decreases by as much as 50% during recumbency.
Severe exercise may increase proteinuria substantially
Reduce obesity Obesity apparently causes glomerulomegaly and proteinuria
Level 3
Decrease elevated homocysteine Hyperhomocystinuria is associated with microalbuminuria and increased cardiovascular risks.
Folic acid, B6, and B12 may lower homocysteine levels
Antioxidant therapies Antioxidant therapies of several types reduce proteinuria in both experimental models and in
patients with diabetic nephropathy
Sodium bicarbonate therapy to correct
metabolic acidosis
NaHCO3 therapy is not antiproteinuric; however, it blocks complement activation in the
tubular compartment and, therefore, may block tubular injury caused by proteinuria
NSAID therapy in severe untreatable
nephrotic syndrome
NSAIDs (both COX 2 and nonspecific COX inhibitors) are antiproteinuric but are also
nephrotoxic. Thus, NSAID use should be reserved for severe untreatable nephrotic syndrome
Other therapies based on animal studies Avoid excessive caffeine, iron overload. Allopurinol, pentoxifylline, mycophenolate therapy
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recovery from LPS-induced proteinuria.25 Therefore, we
reasoned that podocytes are a direct target of CsA,
independent of NFAT inhibition in T cells and found that
CsA blocks the calcineurin-mediated dephosphorylation of
synaptopodin, thereby preserving the phosphorylation-
dependent synaptopodin-14-3-3b interaction (Figure 4).57
Preservation of this interaction, in turn, protects synaptopo-
din from CatL-mediated degradation and preserves a
stable filtration barrier (Figure 4). The inducible expression
of CatL-resistant synaptopodin in podocytes can prevent not
only the LPS-induced degradation of synaptopodin and
proteinuria but also the degradation of the other CatL target
dynamin (Figure 4) and zonula occludens-1, a vital
component of the SD.101 Moreover, the inducible expression
of dominant active calcineurin in podocytes is sufficient to
cause the degradation of synaptopodin, thereby inducing
proteinuria.57 These data unveiled a calcineurin signaling
pathway, which is operative in podocytes and contributes to
the maintenance of kidney filter function (Figure 4). In
contrast to most other calcineurin-controlled signaling
events,106,107,110,111 the antiproteinuric effect of CsA does
not result from the inhibition of NFAT signaling. Altogether,
the antiproteinuric effect of CsA results, at least in part, from
the maintenance of synaptopodin protein levels in podocytes,
which safeguard against proteinuria by maintaining a
stationary podocyte phenotype (Figure 4).57
OUTLOOK
Intense research efforts aimed at deciphering the pathogen-
esis of proteinuria are starting to pay off and novel therapies
are in sight. A CatL-mediated enzymatic disease process in
podocytes suits well to explain the common pathological
feature of podocyte FP effacement that is observed in most
cases of proteinuria (Figure 4). The growing list of targets
that are cleaved by cytosolic CatL harbors potential for renal
protection by stabilizing these substrates. Motility of FP is
directly affected by CatL-mediated proteolysis or by signaling
pathways that change the migratory behavior of podocytes
into a motile phenotype (Figure 4); for example, by activating
Cdc4242,96 and Rac1 signaling.20,42,52 The relevance of these
changes is underscored by the findings that inhibition of
Cdc42 signaling with FP(4)-Mito96 or Rac1 signaling with
NSC23766 or epleronone20 can prevent proteinuria. The
antiangiogenic and antitumor agent, cycloRGDfV, a selective
inhibitor of avb3 integrin,
93 is currently being tested in
clinical trials against a number of human cancers, including
recurrent glioblastoma multiforme,112 pediatric brain tu-
mors,113 and prostate cancer.114 CycloRDGfV also holds
substantial promise for the development of novel antiprotei-
nuric therapeutics by blocking activated uPAR–b3-integrin
signaling and podocyte FP hypermotility.42 The findings that
the antiproteinuric effect of CsA results from a direct effect
on podocytes suggests that nephrologists have been using the
right approach for the wrong reason, and raises the exciting
possibility that other proteinuric diseases, such as diabetic
nephropathy, may also be treated by agents that stabilize the
podocyte cytoskeleton.115 Clearly, this notion will be of more
practical value if the antiproteinuric effect of CsA can be
achieved by lower, non-immunosuppressive doses or if
selective agents can be developed that avoid the serious side
effects of long-term CsA treatment.116 Looking ahead, it will
be important to understand the crosstalk between the
calcineurin–CatL pathways and other proteins and emerging
signaling pathways that govern podocyte actin dynamics and
cell migration,7 including Kibra,117 ROS, Ang II,102,118
transforming growth factor-b,119 TRPC6,120,121 myo-
sins,122,123 or nephrin–nck signaling.23,24,38 Integrating these
other mechanism with the calcineurin–Catl pathway and
identifying the calcineurin–Catl pathway-dependent versus
independent pathways, leading to proteinuria and/or pro-
gressive kidney disease, are necessary work lying ahead. In
conclusion, based on the consideration discussed above,
novel calcineurin (synaptopodin) and CatL substrates
(dynamin, synaptopodin), as well as the inhibition of
cytosolic CatL, itself provide promising starting points for
the development of selective, antiproteinuric, and podocyte-
protective drugs.
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